Osimertinib activates TFEB to trigger hepatocyte cytoplasmic vacuolation-associated cell death
Abstract Osimertinib is a first-line treatment for advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR)-sensitive mutations; however, the severe hepatotoxicity of osimertinib is a challenge that has attracted attention. In this study, we found that osimertinib directly ca...
Сохранить в:
| Главные авторы: | , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMC
2026-01-01
|
| Серии: | Cell Communication and Signaling |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1186/s12964-026-02688-4 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|